Zafgen's ZGN-1061 meets in Phase II for Type II diabetes

Zafgen Inc. (NASDAQ:ZFGN) said the 0.9 mg dose of subcutaneous ZGN-1061 every three days met the primary endpoint in a Phase II trial to treat Type II diabetes in patients failing multiple other antidiabetic agents. Data were presented at the American Diabetes Association meeting in Orlando.

The double-blind, Australian and New Zealand trial enrolled 129 overweight or obese Type II diabetics to receive placebo or 0.05, 0.3 or 0.9 mg subcutaneous ZGN-1061 every three days for 12 weeks. On the primary endpoint, the 0.9 mg dose of ZGN-1061 led to a significant placebo-adjusted improvement in HbA1c from baseline to week 12 of 0.7% (p<0.001). The 0.05 and 0.3 mg doses of ZGN-1061 missed the endpoint, which the company said establishes the 0.9 mg dose as the minimally effective dose...